ImmunoACT

Discover progressive advancements in cancer treatment with Dr. Atharva Karulkar, Co-founder and Head-Scientific Affairs, ImmunoACT, alongside Kavitha Iyer Rodrigues, Founder & CEO, Zumutor Biologics; and Narendra Bhandari, General Partner, seafund as they explore 'Bioengineering Humanity's Future.' "We take T cells from the patient, genetically engineer them into magic bullets, and send them back to cure cancer. It's a personalized, living drug that stays in your body forever, ensuring cancer never returns," explains Dr. Atharva, highlighting how Indian innovation is revolutionizing cancer treatment. Watch this transformative session to understand how Indian innovators are democratizing advanced healthcare by harnessing our immune systems and making cutting-edge treatments accessible to all. Watch the full video to know more: https://lnkd.in/g6xyCfyB nasscom deeptech | Sangeeta Gupta | Kritika M | Sandeep Bahl | Shalini Dewan | Shreya Sharma | Nehal Pandya | Mayank Kumar | Shivam Sareen | Ashish Gupta | Aishwarya K | Ankita Puranik | Arihant Kothari | Khushbu Gupta | Meghna Girish | Prashant verma | Richpal Choudhary | Shivaling Salakki | Vinay Kumar C. | Jeyandran Venugopal | Abhinav Aggarwal | Ajeya Motaganahalli | Anish Agarwal | Anu Acharya | Arun Seth | Ashok Chandavarkar | Atul Batra | Naganand Doraswamy | Narendra Bhandari | Padmaja Ruparel | Palash Gupta #nasscomfutureforge2024 #nasscom #nasscomdeeptech #nasscomstartups

A New Milestone in Cancer Treatment: CAR T-Cell Therapy Launched in India India has taken a giant leap in cancer care with the introduction of ImmunoACT NexCAR19, our first indigenously developed CAR T-cell therapy for blood cancers like B-ALL (B-cell acute lymphoblastic leukemia) and B-NHL (B-cell non-Hodgkin lymphoma). At a recent event hosted by Fortis Memorial Research Institute (FMRI), Gurgaon, leading experts highlighted the groundbreaking potential of this therapy. Developed by a dedicated team from IIT Bombay, led by Mr. Sirish Arya, Mr. Rahul Purwar, and Mr. Atharva Karulkar, NexCAR19 results from 8+ years of rigorous research and innovation. 💡 What Makes CAR T-Cell Therapy Revolutionary? CAR T-cell therapy trains the patient’s own immune cells to recognize and destroy cancer cells, offering a personalized, targeted, and highly effective solution —a ray of hope for patients with relapsed or refractory blood cancers. 🎤 Key Event Takeaways: Pioneers Speak: Insights from Prof. Rahul Purwar, Founder of ImmunoACT, on this indigenously developed therapy. Expert Guidance: Hemato-oncologists Dr. Rahul Bhargava and Dr Vikas Dua explained the treatment process, benefits, and costs (USD 55,000–75,000). 🌍 Proudly Indian, Globally Competitive: Launched under the leadership of ImmunoACT in collaboration with Tata Memorial Centre and Indian Institute of Technology, Bombay, NexCAR19 positions India as a global leader in affordable, cutting-edge cancer care. Read more about the event and NexCAR19 at https://lnkd.in/gqC7vp5F Let’s celebrate this milestone in healthcare innovation—a testament to the power of Indian research and collaboration! #InnovationInHealthcare #CAR_TCellTherapy #CancerCare #MadeInIndia #FortisMemorialResearchInstitute #IITBombay #ImmunoACT #FMRI #BloodCancer #BcellAcuteLymphoblasticLeukemia #BcellNonHodgkinLymphoma #NexCAR19 #TataMemorialCentre #Immunotherapy #CancerTreatment Fortis Healthcare

Meet us at the American Society of Hematology's 66th Annual Meeting, 2024! We're pleased to announce that we will be presenting 2 abstracts at the 66th Annual ASH Meeting and Exposition in San Diego, this December 7 - 11, on a real-world snapshot in the usage of NexCAR19 (Talicabtagene autoleucel) in the treatment of B-NHLs and B-ALL, as well as pre-clinical data from our upcoming Multiple Myeloma CAR-T candidate. NexCAR19 is India's first indigenous and market authorized CAR-T cell therapy born through a collaboration between Indian Institute of Technology, Bombay, Tata Memorial Centre, & ImmunoACT and has now been provided to more than 150 patients in the real-world setting. Reach out to us at helpdesk@immunoact.com to schedule a meeting if you would like to collaborate with us, or to know more about our CAR-T cell therapies, and don't miss our poster presentations! Click on the links in the document to check out our abstracts. Rahul Purwar Atharva Karulkar Hasmukh Jain Shirish Arya Dr. Ashutosh Tripathi Akhilesh Kumar Pandey U HARI KRISHNAN Karan Gera Tata Memorial Centre Department of Biotechnology Biotechnology Industry Research Assistance Council (BIRAC) Alliance for Regenerative Medicine ISCT, International Society for Cell & Gene Therapy Cell & Gene Therapy Insights European Society of Gene and Cell Therapy American Society of Gene & Cell Therapy Indian Institute of Technology, Bombay Aalia Khan. Department of Science & Technology, Government of India Society for Innovation & Entrepreneurship -SINE IIT Bombay Nitin Jain National Cancer Institute (NCI) MD Anderson Cancer Center Carl June Amrita Hospital, Faridabad Amrita Hospital, Kochi Max Healthcare Apollo Hospitals Medanta Basavatarakam Cancer Hospital and Research Institute HOC Vedanta Prashant Mehta Esha Kaul Neeraj Sidharthan Nirali Shah Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) Navin Khattry

In August 2024, The United States' Deputy Secretary of State for Management & Resources, Richard R Verma, spoke at the Centre for Social and Economic Progress (CSEP) about the collaborative efforts between the US & India, in highlighting India's first indigenous CAR-T cell therapy platform borne from Indian Institute of Technology, Bombay & Tata Memorial Centre that is today actualized by NexCAR19™, which received valuable guidance from the National Cancer Institute in Bethesda, MD. Click the link below, beginning 18:14 - https://lnkd.in/dvSTbCAu

At the Apollo Cancer Conclave 2024, NexCAR19 formed a prominent part of the discussions involving B-cell malignancies and their treatment in relapsed/refractory settings. Dr. Lingaraj Nayak, Professor of Medical Oncology (Adult Haematolymphoid Group) at TATA MEMORIAL HOSPITAL, delivered a "How I Treat" track presentation for B-cell acute lymphoblastic leukaemia (B-ALL), wherein NexCAR19's real-world snapshot was discussed. Dr. Padmaja Lokireddy's (Consultant Haematology & BMT, Apollo Hospitals, Jubilee Hills) presentation on treatment options in refractory/relapsed DLBCL also touched upon the optimal sequencing of CAR-T cell therapy for improving clinical outcomes. Dr. Gaurav Narula (Professor of Paediatric Oncology, Tata Memorial Centre) delivered a talk on the journey of NexCAR19 from ideation to the clinic and beyond. Dr. Navin Khattry (Dy. Director & Professor of Medical Oncology, Tata Memorial Centre) delivered a presentation on the use of Allo-SCT in the era of CAR-T cell therapy, elucidating further how these treatment options may fit in real-world settings. The haematolymphoid session also featured a keynote presentation by Dr. Nitin Jain from the MD Anderson Cancer Center, which highlighted their evolving treatment paradigm with CAR-T cell therapies in treating B-ALL. Our thanks to the organizers for providing us with an excellent academic platform for discussing how to provide comprehensive access to NexCAR19 to improve patients' clinical outcomes.

We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com We’re excited to connect with you!

We are pleased to announce that our first patient in Madhya Pradesh has been enrolled for treatment with NexCAR19™ at MGM Medical College's M.Y. Hospital in Indore. This is the latest milestone towards broadening access to our CAR-T cell therapies and aiming to improve overall survival outcomes in patients with relapsed/refractory B-cell cancers. It is also of note that this is the first government hospital in Central India to enroll a patient for treatment with NexCAR19™. https://lnkd.in/dkma-JRB

May the lights of Diwali fill your life with joy, prosperity, and happiness. Happy Diwali!! 🪔 🎉

We are pleased to announce a collaboration with SHALBY Sanar International Hospitals - to provide access to NexCAR19™, and our pipeline CAR-T cell therapies, at their state-of-the-art oncology treatment centres across India, another significant step in our goal of improving survival and quality of life in patients with B-ALL and B-NHL.

At the 19th International Conference of Drug Regulatory Authorities (ICDRA) held in New Delhi this week, following the theme of “Smart Regulation: Delivering Quality Assured Medical Products for All”, we showcased our fully integrated R&D and Manufacturing platform of CAR-T cell therapies, the first of which (NexCAR19™) was successfully market authorized in October 2023 and has since been infused in over 130 patients across India. We strive to achieve and maintain the highest quality and consistency in delivering our life-saving gene-modified cellular therapies, in an endeavour that focuses on adhering to global regulatory standards. Atharva Karulkar Manivasagam S